Top Page
PYC Therapeutics Limited
(Sydney:PYC)
PYC Therapeutics Limited (PYC) vs. iShares MSCI Australia ETF (EWA)
PYC Therapeutics Limited Business Overview & Revenue Model
PYC Therapeutics Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.49M | 23.49M | 22.06M | 15.81M | 16.04M | 3.07M |
| Gross Profit | 23.49M | 23.49M | 22.06M | 14.92M | 15.20M | 2.45M |
| EBITDA | -52.88M | -52.88M | -54.55M | -38.25M | -29.39M | -21.04M |
| Net Income | -50.30M | -50.30M | -37.73M | -22.79M | -13.86M | -17.77M |
Balance Sheet | ||||||
| Total Assets | 183.28M | 183.28M | 91.24M | 37.17M | 45.35M | 57.94M |
| Cash, Cash Equivalents and Short-Term Investments | 153.05M | 153.05M | 66.87M | 15.57M | 29.11M | 51.50M |
| Total Debt | 1.02M | 1.02M | 1.11M | 315.49K | 943.77K | 730.35K |
| Total Liabilities | 13.27M | 13.27M | 10.18M | 8.72M | 5.15M | 4.02M |
| Stockholders Equity | 169.57M | 169.57M | 80.50M | 27.75M | 39.35M | 53.04M |
Cash Flow | ||||||
| Free Cash Flow | -52.54M | -52.54M | -38.90M | -24.91M | -22.17M | -12.38M |
| Operating Cash Flow | -51.56M | -51.56M | -38.59M | -24.42M | -21.78M | -11.79M |
| Investing Cash Flow | -975.40K | -975.40K | -307.04K | -477.12K | 32.68M | -15.52M |
| Financing Cash Flow | 138.66M | 138.66M | 90.19M | 11.44M | -182.36K | 38.56M |
PYC Therapeutics Limited Technical Analysis
PYC Therapeutics Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $581.83M | 16.04 | 15.90% | 0.44% | 7.76% | 1.55% | |
| ― | AU$419.50M | ― | -35.86% | ― | ― | -19.21% | |
| ― | AU$1.82B | ― | -54.37% | ― | ― | -29.93% | |
| ― | AU$285.75M | -3.10 | -90.93% | ― | 456.50% | -457.14% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | AU$697.00M | ― | -40.23% | ― | ― | -5.70% | |
| ― | AU$738.77M | ― | ― | ― | -80.08% | 59.91% |
PYC Therapeutics Limited Corporate Events
PYC Therapeutics Limited is conducting a clinical study titled ‘A Phase 1b Open-Label, Randomized, Single Dose and Repeat Dose Study to Evaluate the Single and Repeat Dose Safety and Tolerability of Intravitreally Administered PYC-001 in Participants With Confirmed OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy.’ The study aims to assess the safety and determine the optimal dosing regimen of PYC-001 in individuals with this genetic condition, which affects vision.
PYC Therapeutics Limited is conducting a Phase 1 clinical study titled ‘A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenously Administered PYC-003.’ The study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of PYC-003 in both healthy adults and adults with a confirmed PKD1 mutation associated with Autosomal Dominant Polycystic Kidney Disease (ADPKD). This research is significant as it explores a potential new treatment for ADPKD, a genetic disorder that currently has limited therapeutic options.
Study Overview: PYC Therapeutics Limited is conducting a Phase 1a open-label study titled ‘SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew)’. The study aims to evaluate the safety and tolerability of PYC-001, a potential treatment for individuals with confirmed OPA1 mutation-associated autosomal dominant optic atrophy (ADOA), a hereditary eye condition that leads to vision loss.
Study Overview: PYC Therapeutics is conducting a Phase 1 open-label study titled A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy. The primary objective is to assess the safety and tolerability of VP-001, a promising treatment for retinal dystrophy associated with PRPF31 mutations, a condition that leads to progressive vision loss.
PYC Therapeutics Limited is conducting a study titled ‘A Repeat-Dose, Open-Label, Four Arm Safety and Efficacy Study of Two Doses of VP-001 (75ug and 120ug) Administered Intravitreally in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy.’ This study aims to evaluate the safety and efficacy of VP-001 in individuals with retinal dystrophy linked to the PRPF31 mutation, who have previously received VP001 treatment.
PYC Therapeutics Limited announced significant progress in its drug development programs during Q3 2025, advancing all four of its precision medicine candidates. Key developments include moving into new study phases for treatments targeting Polycystic Kidney Disease, Retinitis Pigmentosa type 11, Autosomal Dominant Optic Atrophy, and Phelan-McDermid Syndrome. These advancements are crucial for the company as it prepares for upcoming human safety and efficacy read-outs, which could impact its market positioning and offer new hope for patients with unmet medical needs.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has initiated a global Phase 1b clinical trial, known as the MYRTLE study, for its investigational drug PYC-001, aimed at treating Autosomal Dominant Optic Atrophy (ADOA). The study will assess the safety, tolerability, and efficacy of repeat dosing of PYC-001, with initial dosing already administered to the first patient. This trial marks a significant step in establishing clinical proof of concept for PYC-001, potentially leading to a registrational study and offering hope for patients with no current treatment options.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has announced its Annual General Meeting will be held on November 18, 2025, at the Harry Perkins Institute of Medical Research in Western Australia. This meeting is significant for stakeholders as it provides insights into the company’s strategic direction and operational updates, reinforcing its commitment to advancing RNA therapies in the biotechnology sector.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has released a presentation providing an update on its business operations. The presentation emphasizes the company’s ongoing commitment to advancing its therapeutic solutions, although it advises stakeholders to consider the inherent risks and uncertainties associated with forward-looking statements.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited announced an upcoming investor webinar scheduled for October 13, 2025, to discuss recent changes in its board and management team, as well as progress in its four drug development programs. This event reflects the company’s ongoing commitment to transparency and engagement with stakeholders, highlighting its strategic focus on advancing its RNA therapeutic pipeline and strengthening its industry position.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has announced changes in its board of directors, with new appointments and final interest notices for several directors. These changes are part of the company’s ongoing efforts to strengthen its leadership team as it continues to advance its RNA therapeutic programs, which could impact its market positioning and stakeholder interests.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics has announced significant changes to its Board and Executive management team to support its growth ambitions. Dr. Rohan Hockings has been re-appointed as Managing Director, and Prof. Ian Constable joins as a Non-Executive Director, bringing extensive experience in drug development. These changes are part of PYC’s strategy to advance its pipeline of drug candidates into late-stage clinical development, preparing for substantial growth and multiple concurrent clinical programs.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has issued a correction to a previous trading halt request, clarifying that the halt is related to pending changes in the company’s board and management, not a capital raising as initially stated. This announcement underscores the company’s focus on restructuring its leadership, which may impact its strategic direction and operations, potentially influencing stakeholder confidence and market positioning.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has requested a trading halt on its securities pending an important announcement concerning changes to its board and management. This move is part of a broader strategy that includes a proposed capital raising, which could have significant implications for the company’s future operations and market positioning.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited announced the completion of dosing in its Phase 1 Single Ascending Dose study for its drug candidate PYC-001, aimed at treating Autosomal Dominant Optic Atrophy (ADOA), a blinding eye disease with no current approved treatments. The company will present promising safety and early efficacy data at the Neuro-Ophthalmology Society of Australia conference, indicating no serious adverse events and an early trend of improvement in visual acuity. PYC plans to advance PYC-001 into a global Phase 1/2 Multiple Ascending Dose study in Q4 2025, aiming to establish clinical proof-of-concept before progressing to a registrational trial.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited announced that safety data from the Phase 1a/1b clinical trial of their drug candidate PYC-003, aimed at treating Polycystic Kidney Disease, will be presented at the ANZSN conference. The data from the trial’s completed dose cohorts show a favorable safety profile, with no serious adverse events or signs of renal injury, supporting the drug’s potential efficacy and safety in further trials.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has released its Corporate Governance Statement, highlighting its adherence to the ASX Corporate Governance Principles and Recommendations. The company emphasizes its commitment to ethical standards and shareholder value, outlining strategies for management oversight and performance monitoring. The board is responsible for setting strategic directions, monitoring performance, and ensuring compliance with legal and regulatory objectives. This governance framework aims to enhance shareholder wealth and address the interests of various stakeholders.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement confirms the company’s adherence to the ASX Corporate Governance Council’s recommendations, highlighting their commitment to transparency and accountability in management and oversight.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has released its 2025 Annual Report, highlighting its strategic initiatives and financial performance. The report underscores the company’s commitment to advancing its therapeutic pipeline, which could enhance its position in the biotechnology industry and potentially benefit stakeholders through improved market competitiveness.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics reported a 14.5% increase in income from ordinary activities for the year ending June 30, 2025, reaching $26.17 million. However, the company also experienced a 33.3% increase in losses, amounting to $50.3 million, and did not declare any dividends. The company increased its equity share in Vision Pharma Limited to 97.1%, indicating a strategic move to consolidate its holdings.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has announced the progression of its clinical trials for PYC-003, a drug candidate for Polycystic Kidney Disease (PKD). The Safety Review Committee has approved the escalation to the highest dose cohort in the Single Ascending Dose study, and dosing has commenced for PKD patients in Part B of the study. This advancement positions PYC to proceed to repeat dose studies in late 2025, potentially leading to a Phase 2/3 trial to support a New Drug Application.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited held a Q3 investor webinar to provide updates on its business activities. The presentation emphasized the reliance on publicly available information and included cautionary notes about forward-looking statements, highlighting potential risks and uncertainties that could impact future outcomes.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$3.90 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.